PRELUDE THERAPEUTICS INC
PRLDNASDAQTrading Snapshot
- Day Range
- $3.93 – $4.03
- 52-Week Range
- $1.15 – $6.83
- Volume
- $3.42B
- Avg Volume
- $3.77B
- Shares Outstanding
- 56.9M
- Next Earnings
- Nov 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $12M
- Last Q Revenue
- $6M
- P/E Ratio
- -5.0
- P/S Ratio
- 10.1x
- EPS (TTM)
- $-0.61
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −17.1%
Why Investors Own PRLD
- ✓High-growth profile — revenue up +3.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 34% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PRELUDE THERAPEUTICS INC
PRLD
StockOtter · stockotter.spaceAbout PRELUDE THERAPEUTICS INC
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
WILMINGTON, Del., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the H.C.
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
WILMINGTON, Del., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company to
Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?
The consensus price target hints at a 58.4% upside potential for Prelude Therapeutics (PRLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisio
ADAR1 Capital Management LLC Makes New Investment in Prelude Therapeutics Incorporated $PRLD
ADAR1 Capital Management LLC purchased a new position in shares of Prelude Therapeutics Incorporated (NASDAQ: PRLD) during the undefined quarter, according to the company in its most recent Form 13F filing with the Secur
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why
Prelude Therapeutics (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).